Why did the CSL share price outperform the ASX 200 in February?

The healthcare giant produced healthy outperformance in February.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have managed to outperform the ASX 200 in February
  • The ASX healthcare share reported its HY23 result, showing 10% underlying net profit growth
  • CSL is expecting to generate underlying net profit of between $2.7 billion to $2.8 billion in FY23

The CSL Limited (ASX: CSL) share price managed to beat the return of the S&P/ASX 200 Index (ASX: XJO) during February 2023.

As of midday trading, CSL shares were flat for the month, while the ASX 200 Index had dropped around 3%.

The difference in performance may be explained by two factors.

On the ASX 200 side of things, there has been a sizeable decline in the share prices of some of the largest ASX blue chips, which has an outsized impact on the index.

For example, BHP Group Ltd (ASX: BHP), Commonwealth Bank of Australia (ASX: CBA), and Rio Tinto Limited (ASX: RIO) have all seen their share prices drop, which has pulled the ASX 200 lower.

CSL released its FY23 half-year result mid-month, which investors are likely to have taken into account when considering the CSL share price.

Let's have a look at some of the numbers.

Earnings recap

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

CSL likes to tell investors its numbers in constant currency terms so that they are more easily comparable to the last result. This makes it much clearer in the case of foreign exchange rates causing any rise or fall.

The ASX healthcare share reported that revenue increased by 25% in constant currency terms, while underlying net profit after tax (NPAT) increased by 10% to $1.82 billion.

CSL reported strong growth of immunoglobulin and albumin sales, as well as record levels of plasma collections. It also revealed strong growth in its "market leading" haemophilia product IDELVION and "key speciality product" KCENTRA.

It also said its influenza vaccine business, CSL Seqirus, achieved "strong performance".

The ASX healthcare share noted the successful closure of its Vifor acquisition – it achieved around 15% revenue growth, with integration well underway and cost synergies on track. Vifor provides CSL with "leadership across an attractive portfolio focused on renal disease and diseases of iron deficiency".

CSL also noted a licence agreement for late-stage self-amplifying mRNA vaccine technology.

The dividend declared was US$1.07 per share and, in Australian dollar terms, it was A$1.55 per share, up 9%.

Did the outlook impact the CSL share price?

Investors are often forward-looking, so what the company has to say about its outlook could have a major impact on market sentiment. It didn't seem to be much of a surprise to the market.

The strong growth in plasma collection and immunoglobulins "is expected to continue", CSL said.

The company is also planning to launch HEMGENIX in the US, which it said would change people's lives. Management also said that the rest of its research and development pipeline is in "great shape".

CSL Seqirus continues to perform "strongly" and will deliver "another profitable year", though a loss is expected in the second half because of the seasonal nature of the business.

The company's underlying net profit is expected to be between $2.7 billion to $2.8 billion at constant currency.

CSL share price snapshot

While CSL shares were flat for February 2023, they are up more than 5% in 2023 to date.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »